Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence
between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy …

Acute Lymphoblastic Leukemia in Children | New England Journal of Medicine Skip to main
content The New England Journal of Medicine homepage Advanced Search SEARCH …

Importance Standard chemotherapy for first relapse of B-cell acute lymphoblastic leukemia
(B-ALL) in children, adolescents, and young adults is associated with high rates of severe …

Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent effects in relapsed
and/or refractory pre–B cell acute lymphoblastic leukemia (B-ALL), but antigen loss is a …

Abstract Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in
hematologic complete remission after multiagent therapy exhibit minimal residual disease …

Chimeric antigen receptor (CAR)–modified T cells with anti-CD19 specificity are a highly
effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia …

Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-
adapted based on clinical features, leukemia genomics and minimal residual disease …

New high-dimensional, single-cell technologies offer unprecedented resolution in the
analysis of heterogeneous tissues. However, because these technologies can measure …

Monitoring of minimal residual disease (MRD) has become routine clinical practice in
frontline treatment of virtually all childhood acute lymphoblastic leukemia (ALL) and in many …

Importance Minimal residual disease (MRD) refers to the presence of disease in cases
deemed to be in complete remission by conventional pathologic analysis. Assessing the …